Equity Overview
Price & Market Data
Price: $21.23
Daily Change: +$0.23 / 1.08%
Daily Range: $20.88 - $21.88
Market Cap: $1,359,900,416
Daily Volume: 50,104
Performance Metrics
1 Week: 7.28%
1 Month: 18.08%
3 Months: 26.14%
6 Months: 23.65%
1 Year: 31.21%
YTD: 10.75%
Company Details
Employees: 108
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.